araag2/HINT huggingface dataset:
Clinical trial NCT00409214 (phase 2, status: completed)
Conditions: glioma, glioblastoma multiforme, anaplastic astrocytoma
ICD codes: L51.0, L51.8, L51.9, C84.67, C84.77, C84.7A, C84.60, C84.70, C84.62, C84.66
Drugs: ls11 (talaporfin sodium)
SMILES: CCC1=C(C)\C2=C\C3=C(C=C)C(C)=C(N3)\C=C3/N=C([C@@H](CCC(O)=O)[C@@H]3C)/C(/CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C3\N\C(=C/C1=N2)C(C)=C3C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have primary or recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA)
             undergoing planned tumor resection

          -  Have a right sided, supratentorial frontal or temporal lobe tumor

          -  Have right hand dominance

          -  Be adults aged >18 years

          -  Have a Karnofsky Performance Status score >70

          -  Have a estimated life expectancy of >12 weeks

          -  Have completed any prior antineoplastic therapy at least 4 weeks prior to surgery and
             be recovered from acute side effects

          -  Must have the understanding and ability to sign an informed consent document

          -  Be male or non-pregnant, non-lactating females. Patients who are fertile must agree to
             use an effective method of contraception during participation in the study

          -  Have a negative serum or urine pregnancy test within 14 days prior to treatment (if
             patient is a female of childbearing potential).

        Exclusion Criteria:

        Patients must be excluded if any of the following apply:

          -  Have tumors <2 cm in diameter

          -  Have inadequate organ function as evidenced by: PT or PTT >1.5 × control ; Platelet
             count <100,000/mm3 ; WBC <2,500/mm3 ; Neutrophils <2000/mm3 ; Hemoglobin <9 g/dL

          -  Be concurrently participating in another clinical trial involving experimental
             treatment

          -  Have any concurrent diseases or conditions that in the opinion of the investigator
             impair the patient's ability to complete the trial such as psychological, familial,
             sociological, geographical or medical conditions which in the Principal Investigator's
             opinion could compromise compliance with the objectives and procedures of this
             protocol or obscure interpretation of the trial's data are excluded.

          -  Have psychological, familial, sociological, geographical, or medical conditions which,
             in the Investigator's opinion, could compromise compliance with the objectives and
             procedures of this protocol or obscure interpretation of the trial data.

          -  Have a known sensitivity to porphyrin-type drugs or known history of porphyria
Clinical trial NCT01409031 (phase 2, status: terminated)
Conditions: persistent pulmonary hypertension, respiratory failure
ICD codes: J95.821, P28.5, J96.01, J96.02, J96.11, J96.12, J96.91
Drugs: intravenous sildenafil
SMILES: CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1
Reason stopped: 
    this trial was terminated early due to lack of recruitment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent from legally acceptable guardian

          -  PPHN or hypoxemic respiratory failure associated with:

               -  Idiopathic PPHN

               -  Meconium aspiration syndrome

               -  Respiratory distress syndrome

               -  Sepsis

               -  Pneumonia

          -  Greater than or equal to 35 weeks gestation

          -  Age at enrollment less than 72 hours

          -  Moderate hypoxemic respiratory failure, with 12<OI<35 (oxygenation index, calculated
             as FiO2 * mean airway pressure * 100 / postductal PaO2)

          -  Absence of structural heart disease (except patent ductus arteriosus, atrial septal
             defect <1cm, or muscular ventricular septal defect < 2mm)

          -  Absence of lethal congenital anomaly

          -  Not participating in another concurrent experimental study

        Exclusion Criteria:

          -  Prior or immediate need for iNO or ECMO

          -  Profound hypoxemia: qualifying PaO2 <30 mmHg, from a blood gas drawn within 30 minutes
             of starting study drug infusion.

          -  Hypotension: Mean arterial pressure <35 mmHg

          -  Congenital heart disease, except patent ductus arteriosus, atrial septal defect <1cm,
             or muscular ventricular septal defect <2mm

          -  Congenital diaphragmatic hernia or lung hypoplasia syndromes, diagnosed on the basis
             of prolonged oligohydramnios

          -  Active seizures

          -  Apgar score of <3 at 5 minutes

          -  Bleeding diathesis

          -  Receipt of any other experimental drug or device

          -  Receipt of any prohibited concurrent medication:

               -  Potent cytochrome P450 3A4 inhibitors (e.g., erythromycin, ketoconazole,
                  itraconazole and protease inhibitors)

               -  Endothelin antagonists (e.g. Tracleer/bosentan)

               -  Intravenous nitrates or nitric oxide donors

          -  Known hereditary degenerative retinal disorders such as retinitis pigmentosa.

          -  In the opinion of the investigator, a subject who is not likely to complete the study
             or would be considered inappropriate for the study, for any reason.
Clinical trial NCT00225758 (phase 2, status: terminated)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: lapatinib
SMILES: CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with histologically or cytologically proven metastatic breast cancer.

          -  Patients with either estrogen or progesterone receptor positivity on the most recently
             examined tumor biopsy.

          -  Patients must have most recently been using an anti-estrogen (tamoxifen, toremifene,
             raloxifene, or fulvestrant) or an aromatase inhibitor.

          -  Patients must have had either a partial response or better, or stable disease for 24
             weeks or longer, followed by disease progression, on the current or most recent
             hormonal therapy for management of metastatic breast cancer.

          -  Patients must be enrolled within six weeks of defining disease progression on hormonal
             therapy.

          -  Patients must have stopped fulvestrant at least four weeks prior and other endocrine
             therapy at least two weeks prior to enrollment on study.

          -  Patients must have either measurable disease or at least one evaluable bone lesion
             that has not been irradiated. Measurable disease is not necessary.

          -  Estimated life expectancy of at least 6 months.

          -  ECOG performance status 0-2.

          -  Adequate hematologic, hepatic, and renal function.

          -  Patients must be post-menopausal, or they must be practicing either abstinence or an
             adequate method of contraception, or their sexual partner must be sterile.

          -  All patients must be able to swallow, retain, and absorb oral medications.

          -  All patients must be able to give informed consent indicating that they are aware of
             the investigational nature of this study.

        Exclusion Criteria:

          -  Patients may not have received an investigational agent within the prior four weeks.

          -  Patients may not have received trastuzumab within three weeks of study entry.

          -  Patients may not have had major surgery within the prior two weeks.

          -  Patients may not have Class III or IV heart failure as defined by the NYHA functional
             classification system.

          -  Patients may not have a left ventricular ejection fraction < 40% based on MUGA or
             echocardiogram.

          -  Patients may not have uncontrolled brain metastases or leptomeningeal disease.

          -  Patients may not have rapidly progressive visceral metastases.

          -  Patients may not have a serious illness or conditions including clinically significant
             cardiac disease, angina pectoris, serious psychiatric disorder, or an active
             infection.

          -  Patients may not be receiving concurrent medications (listed in the protocol) which
             may interact with lapatinib during treatment with lapatinib.
Clinical trial NCT00191815 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, cisplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  You are female in the age of 18 to 75 years old.

          -  You have been diagnosed with the metastatic breast cancer.

          -  You have desire and an opportunity to visit your doctor in medical site, both during
             realization of the active treatment program, and within 24 months of medical follow
             up.

          -  You must sign this informed consent form

        Exclusion Criteria:

          -  You are pregnant or breastfeeding.

          -  Your laboratory parameters fall outside the limits, admitted by requirements of the
             present clinical study.

          -  You have been diagnosed with serious concomitant or acute infectious disease.

          -  You have used experimental medications within the last month.
Clinical trial NCT00380588 (phase 2, status: completed)
Conditions: biliary tract cancer
ICD codes: C24.9, C24.8
Drugs: gemcitabine, cisplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological diagnosis of biliary tract cancer

          -  Measurable disease must be at least one lesion

          -  Chemotherapy-naïve

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Estimated life expectancy no less than 3 months

        Exclusion Criteria:

          -  radiological or clinical evidence of pulmonary fibrosis or interstitial pneumonia
Clinical trial NCT01011868 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: bi 10773 placebo, bi 10773 low dose, bi 10773 high dose, bi 10773 placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. Signed and dated written informed consent by date of Visit 1 in accordance with Good
             Clinical Practice (GCP) and local legislation

          2. Male and female patients with a diagnosis of Type 2 Diabetes Mellitus treated with a
             stable dose of basal insulin with or without concomitant metformin and / or
             sulfonylurea.

          3. Glycosylated hemoglobin A1c (Type A, subtype 1c) of >7.0% and < or = 10% at Visit 1
             (screening)

          4. Suitability for trial participation according to investigator's judgment (evaluating
             all alternative treatment options and in consideration of the patient completing the
             study)

          5. Age > or =18 years at Visit 1 (screening)

          6. BMI < or = 45 kg/m2 (Body Mass Index) at Visit 1 (screening)

        Exclusion criteria:

          1. Patients with poorly controlled hyperglycemia

          2. Frequent (at the discretion of the investigator) episodes of hypoglycemic events on
             basal insulin therapy

          3. MI, stroke, or TIA within 3 months prior to obtaining informed consent

          4. Impaired hepatic or renal function; gastric surgery; cancer within the last 5 years;
             blood dyscrasias

        6. Treatment with other anti-diabetics, anti-obesity medications, steroids or thyroid
        hormones, participation in another trial with an investigational drug 7. Pre-menopausal
        women on insufficient birth control 8. Alcohol or drug abuse
Clinical trial NCT00615199 (phase 2, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: cp-690,550, cp-690,550, cp-690,550, placebo
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must be at least 18 years of age at screening

          -  Males and females with clinical evidence of Crohn's disease for at least 3 months
             duration at screening

          -  Subjects with moderate to severe Crohn's Disease at baseline, as defined by a Crohn's
             Disease Activity Index (CDAI) score of 220-450 inclusive

        Exclusion Criteria:

          -  Subjects currently receiving immunosuppressants, interferon, anti-TNFa

          -  Subjects with evidence of hematopoietic disorders

          -  Subjects with evidence of active or latent TB
Clinical trial NCT00564720 (phase 2, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gemcitabine, gemcitabine, erlotinib, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    due to poor accrual of the study
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed pancreatic cancer.

          -  Measurable disease.

          -  Absence of ascites or obstructive jaundice.

          -  ECOG Performance Status 0-2.

          -  Adequate liver kidney and bone marrow function.

          -  Written informed consent.

        Exclusion Criteria:

          -  Chronic diarrheic syndrome.

          -  Uncontrolled brain metastases after radiation.

          -  Liver infiltration over 50%.

          -  Peripheral neuropathy ≥ 2.

          -  No second primary malignancy within the past 5 years, except non-melanomas skin cancer
             or in situ carcinoma of the cervix.

          -  No active uncontrolled infection.

          -  Active cardiac disease : unstable angina or onset of angina within last 3 months,
             myocardial infarction within 6 months, congestive heart failure > class II, cardiac
             ventricular arrhythmias requiring anti-arrhythmic therapy.

          -  Women who are pregnant or lactating.
Clinical trial NCT00151398 (phase 2, status: completed)
Conditions: alzheimer disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: lecozotan sr, donepezil
SMILES: C[C@H](CN(C(=O)C1=CC=C(C=C1)C#N)C1=CC=CC=N1)N1CCN(CC1)C1=CC=CC2=C1OCCO2, O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of probable AD according to the NINCDS-ADRDA criteria.

          -  Able to give informed consent. Patient' s caregiver must consent to participate in the
             study.

        Exclusion Criteria:

          -  Use of medications for cognitive enhancement within 3 months of baseline.

          -  Significant neurologic disease other than AD that may affect cognition.
Clinical trial NCT01664637 (phase 2, status: terminated)
Conditions: diabetic gastroparesis
ICD codes: K31.84
Drugs: 10 mg tzp-102, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    insufficient efficacy in planned interim futility analysis
  
Eligibility criteria:

        Inclusion Criteria:

          -  18 to 80 years of age inclusive

          -  Type 1 or type 2 diabetes mellitus

          -  History of symptoms of gastroparesis for at least 3 months leading up to the Screening
             Visit

          -  Documented delayed gastric emptying

          -  Upper gastrointestinal obstruction ruled out by endoscopy or barium scan

          -  Concomitant medications must be stable for at least 2 weeks leading up to the
             Screening visit and must be maintained during the study.

          -  Females of child-bearing potential must have a negative serum pregnancy test and use
             (and agree to continue to use throughout the study) an acceptable form of
             contraception

        Exclusion Criteria:

          -  Gastrectomy, bariatric surgery, fundoplication or vagotomy/pyloroplasty

          -  Has had or plans to have endoscopic pyloric injections of botulinum toxin within 6
             months prior to the Screening Visit or during the study

          -  NG, PEG or PEJ feeding tube or inpatient hospitalization for gastroparesis within 2
             weeks prior to the Screening Visit

          -  Required parenteral nutrition for treatment of gastroparesis within 2 months prior to
             the Screening Visit

          -  Active gastric pacemaker within 3 months prior to the Screening Visit
Clinical trial NCT00456716 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: sorafenib
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Age > 18

          -  Life expectancy > 12 weeks

          -  Biopsy-proven BAC or adenocarcinoma

          -  Willing to provide smoking status

          -  Selected IIIB or stage IV cancer that is incompletely resected or unresectable

        Exclusion Criteria:

          -  O2 saturation < 88% on room air

          -  Pregnant or nursing women

          -  Surgery or radiation therapy within 4 weeks of starting study

          -  Major heart condition within 6 months of starting therapy

          -  Certain concomitant medications prohibited
Clinical trial NCT00478179 (phase 2, status: completed)
Conditions: postherpetic neuralgia, pain
ICD codes: B02.22, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: transdermal/patch (bupivacaine tts [eladur™])
SMILES: CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or females age 21 years or older.

          -  Pain in thoracic or lumbar regions for a minimum of 90 days after crusting of Herpes
             Zoster (HZ) lesions.

          -  Stable prescribed medications regimen (including opioids, anticonvulsants, and
             tricyclic antidepressants).

          -  Intact, unbroken skin over the painful area to be treated.

          -  Body Mass Index (BMI) no more than 35 kg/m2.

        Exclusion Criteria:

          -  Active HZ lesions, dermatitis, Central Nervous System (CNS) injury.

          -  Any immunosuppressed condition, including but not limited to AIDS/HIV and Hodgkin's
             lymphoma.

          -  Pain control by nerve block or neurosurgical intervention.

          -  Evidence of clinically significant hepatic, gastrointestinal, renal, hematologic,
             urologic, neurologic, respiratory, endocrine or cardiovascular system abnormalities,
             psychiatric disorders, or acute infection.

          -  Connective tissue disorders (systemic lupus erythematosus, scleroderma, mixed
             connective tissue disease).

          -  Recent use (within 30 days preceding the first treatment visit) of any topically
             applied pain medication, such as nonsteroidal anti-inflammatory drugs, menthol, methyl
             salicylate, local anesthetics (including Lidoderm®), steroids or capsaicin products on
             the painful areas.

          -  Significant pain of an etiology other than PHN, for example, compression-related
             neuropathies (e.g., spinal stenosis), fibromyalgia or arthritis. Patients must not
             have significant ongoing pain from other cause(s) that may interfere with judging PHN
             related pain.

          -  Participation in a clinical trial of an investigational product or device within 30
             days of the screening visit or concurrently during the conduct of this study.
Clinical trial NCT00490542 (phase 2, status: completed)
Conditions: bipolar disorder, bipolar depression, depression
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32, F32.A, F53.0, P91.4, Z13.31, Z13.32, F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: ziprasidone (geodon), placebo
SMILES: ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of bipolar disorder type II, or unipolar major depressive disorder

          -  If female, non-pregnant/non-lactating

          -  If a sexually active female of reproductive potential, must be using adequate
             contraception (i.e., oral contraceptives, barrier protection, or prior tubal ligation)

          -  Currently meets Diagnostic and Statistical Manual, 4th edition (DSM-IV) criteria for a
             major depressive episode, and presence of 2 or 3 DSM-IV manic criteria, present for
             the majority of the time during the past week.

          -  All other baseline psychotropic drugs will be allowed to be continued unchanged.
             However, if antidepressant use has been initiated in the previous 2 months, or was
             thought to be contributing to the depressive mixed state, then antidepressant
             medications would be discontinued 4 weeks before starting the study.
Clinical trial NCT01252186 (phase 2, status: completed)
Conditions: hemostasis, oral contraceptive
ICD codes: T38.4X1A, T38.4X1D, T38.4X1S, T38.4X2A, T38.4X2D, T38.4X2S, T38.4X3A
Drugs: 91-day levonorgestrel oral contraceptive, 28-day levonorgestrel oral contraceptive, 28-day desogestrel oral contraceptive
SMILES: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Premenopausal, non-pregnant, non-lactating women age 18-40 years old

          -  Body Mass Index (BMI) ≥18 kg/m² and <30 kg/m²

          -  Regular spontaneous menstrual cycle

          -  Others as dictated by FDA-approved protocol

        Exclusion Criteria:

          -  Any condition which contraindicates the use of combination oral contraceptives

          -  Any history of, or active, deep vein thrombosis, pulmonary embolism, or arterial
             thromboembolic disease within one year of screening

          -  Any known genetic component for thrombophilia including Factor V Leiden mutation,
             prothrombin mutation, protein C deficiency, protein S deficience, or antithrombin III
             deficiency

          -  Others as dictated by FDA-approved protocol